Objective: To compare the ability of biochemical indices of insulin resistance (IR) with metabolic syndrome (MetS) classifications to predict changes in blood glucose control over a 3-year period in overweight and obese subjects. Design: This was a longitudinal, prospective study, with data collected at baseline, 18 and 36 months. Subjects and methods: A total of 175 overweight (body mass index (BMI)425 kg m À2 ) and obese (BMI430 kg m À2 ) subjects were enrolled in the study. The IR indices assessed included fasting insulin concentration, the insulin/glucose-derived indices, homeostasis assessment model of insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI), the insulin/triglyceride-derived McAuley index, plasma adiponectin concentration and the triglyceride (trig) and high-density lipoprotein (HDL)-cholesterol ratio (trig:HDL). The two MetS classifications were assessed according to the definitions of the National Cholesterol Education Program-Third Adult Treatment Panel (NCEP-ATPIII) and the International Diabetes Federation (IDF). The potential of the IR indices and MetS classifications at baseline to predict the development of impaired fasting glucose (IFG) was examined using receiver-operator characteristic (ROC) curve analysis and analysis of variance. Results: Complete data were collected on 158 subjects. In all, 51 (32%) subjects developed IFG during the study. The analysis of variance showed significant differences between the IFG and normoglycaemic group in the baseline values of the McAuley index, trig:HDL, plasma adiponectin concentration and prevalence of the MetS. The ROC curve analysis confirmed this result and showed that the strongest predictors of IFG were baseline trig:HDL and IDF MetS classification, followed in order by the McAuley index, plasma adiponectin concentration and NCEP-ATPIII MetS classification. In contrast, the baseline values of fasting insulin, HOMA-IR and QUICKI did not predict IFG. Discussion: This study showed that the IR indices, derived, in part, from plasma triglyceride concentration, were sensitive predictors for the development of IFG in normoglycaemic overweight and obese subjects. Indices derived from glucose and insulin did not identify this at-risk group. The study also showed that the presence of MetS and its abnormalities of an increased trig:HDL ratio and low plasma adiponectin concentration were all sensitive predictors of IFG.
Introduction
Normal glucose tolerance is dependent on the interaction between insulin sensitivity and secretion, with impairment of these processes leading to glucose intolerance and type 2 diabetes. 1 The response of insulin secretion to oral glucose is complex and is characterized by primary and secondary phases that are influenced by other stimuli, such as previous exposure to glucose, gastrointestinal hormones and the presence or absence of insulin resistance (IR). 2 The development of IR involves a reduced response of the liver and peripheral tissues to insulin action, and is associated with metabolic abnormalities such as dyslipidaemia and haemodynamic disturbances, including hypercoagulability and enhanced formation of atheroma. Although these abnormalities in insulin function are more common in overweight subjects, 3, 4 not all overweight subjects will progress to impaired glucose tolerance. 5 It is therefore important that overweight subjects at an increased risk of developing glucose intolerance and incipient diabetes are identified as early as possible so that corrective lifestyle changes and therapy can be initiated. Numerous indices have been proposed to identify IR, although the 'gold standard' method remains the euglycaemichyperinsulinemic clamp, which involves continuous intravenous infusion of insulin and measurement of the glucose disposal rate to calculate the insulin sensitivity index. 6 The clamp procedure is, however, technically demanding and invasive, and is therefore limited to research or clinical applications in a small number of patients.
Investigators have therefore sought more practical methods for assessing IR, the simplest of these being measurement of fasting insulin and glucose concentrations, with the results being expressed as either the reciprocal of insulin concentration (1/insulin) 7 or the glucose-to-insulin ratio. 8 Both these indices have a relatively low degree of correlation with euglycaemic clamp data and have been superseded by a range of more complex mathematical models that provide more consistent and accurate information. 1 A majority of these models are derived from glucose and insulin levels, either from numerous separate data points, as in the frequently sampled intravenous glucose tolerance test, 9 or as a single fasting sample in the case of the homeostasis model assessment index, HOMA-IR. A similar commonly used model is the quantitative insulin sensitivity check index (QUICKI), calculated as the log transformation of HOMA-IR. 10 More recently, an index incorporating fasting insulin and triglyceride levels, the McAuley index, has also been shown to be a sensitive marker of IR 11 and has attracted increasing use in clinical research. The presence of the metabolic syndrome (MetS) itself is also often used as a surrogate marker of IR, 12 with its characteristic abnormalities of a raised triglyceride (trig) to highdensity lipoprotein (HDL)-cholesterol ratio (trig:HDL) 13 and low circulating levels of the insulin-sensitizing adipocytokine, adiponectin, [14] [15] [16] shown to correlate with the degree of IR.
A majority of studies that have evaluated indices of IR have been cross-sectional designs and have, in the main, determined the ability of the indices to identify individuals who develop overt diabetes. This study differs from these investigations by obtaining prospective data from overweight and obese subjects over a 3-year period and comparing the potential of indices of IR with two different metabolic syndrome classifications for predicting the development of impaired fasting glucose (IFG).
Materials and methods

Study design
This study was a 3-year prospective analysis of 175 subjects (116 women, 59 men), aged 18- 
Clinical parameters
The study participants were requested to fast for 10 h and attend a clinic appointment between 0700 and 1000 h. A brief medical history was recorded that included ethnicity, details of concomitant disorders, current medications and smoking history. Anthropometric assessment included height measured in bare feet using a Harpenden stadiometer (Holtain Ltd., Crosswell, UK), weight and percentage of body fat obtained using a body fat analyser (Tanita Corp., Tokyo, Japan) and waist circumference measured at the narrowest point between the lower costal border and the top of the iliac crest. BMI was calculated as weight (kg) per height 2 (m).
Blood pressure was measured in duplicate in the sitting position using an automated measuring device (Omron 705CP, Omron Matsusaka Co Ltd, Japan), with the mean value being determined and expressed as mean arterial pressure, calculated as systolic pressure þ (systolic pressure Àdiastolic pressure)/3. The subjects were classified as having MetS according to the definitions of the National Cholesterol Education Program-Third Adult Treatment Panel (NCEP-ATPIII) 17 and the International Diabetes Federation (IDF).
18
The participants were classified as insulin resistant if their HOMA-IR was X1.80. This value represents the 75th percentile of the background population under analysis, a value recommended by the 1998 World Health Organisation guidelines to define IR. 19 
Biochemical parameters
Venous blood samples were collected with minimal stasis into ethylenediaminetetraacetic acid and sodium fluoride anticoagulated tubes and plasma obtained by centrifugation
Predictors of glucose dysregulation in obesity BI Shand et al at 2000 g at 4 1C for 10 min within 1 h of sample collection. Plasma glucose, HDL cholesterol and triglyceride concentrations were determined using an Aeroset analyser (Abbot Laboratories, Illinois, IL, USA) and plasma insulin concentration was measured using an electrochemiluminescence immunoassay (Roche Diagnostics, Indianapolis, IN, USA). Plasma adiponectin concentration was measured in duplicate using a radioimmunoassay (LINCO Research Inc., Missouri, MO, USA). We have shown previously that this adiponectin assay has an intra-assay variation of 8.8% and interassay variation of 9% and that frozen storage of plasma samples for up to 30 months has no effect on adiponectin levels. 20 
Derived indices of insulin resistance
The homeostatic model assessment index, HOMA-IR, was calculated using the HOMA-CIGMA model, 21 QUICKI as 1 per log fasting glucose (mg per 100 ml) þ log fasting insulin (mU l )). 11 The trig:HDL ratio was calculated from the fasting lipid profile.
Statistical analysis
Statistical analyses were carried out using Statistix (Analytical Software, Tallahassee, FL, USA). The ShapiroWilk test was used to determine whether or not the data were normally distributed. This test showed that with the exception of mean arterial pressure, all the variables were not normally distributed and therefore the data were expressed as median and interquartile range and non-parametric tests were used for the statistical analyses. Statistical significance was inferred for P-values p0.05. For statistical analysis, the subjects were grouped according to whether or not they developed IFG (fasting plasma glucose X5.6 mmol l
À1
) during the study. Descriptive statistics of the variables in the two groups at the three time points were then calculated. The baseline data of the two groups were compared using the Wilcoxon rank-sum test for continuous variables and the chi-square test for categorical variables. Changes in the parameters during the study were analysed using the Wilcoxon signed-rank and McNemar's chi-square tests. The ability of the IR indices and the two MetS classifications to identify individuals who developed IFG from those who did not was assessed by calculation of the area under the curve of receiver-operator characteristic (ROC) graphs.
Results
Data at all three time points were obtained from 158 of the 175 subjects enrolled in the study. Of the 17 subjects (9.7%) who did not complete the study, 4 were withdrawn because of serious concomitant disorders, 1 died of breast cancer and 12 were lost to follow-up. Table 1 summarizes the comparison between subjects who were consistently normoglycaemic (n ¼ 107) and subjects who developed IFG during the study (n ¼ 51). Neither group had significant changes in lipid-lowering regimes during the study, with statin therapy being started in six subjects in the normoglycaemic group and four subjects in the IFG group, while statin therapy was stopped during the study in five normoglycaemic subjects.
At baseline, the subjects who developed IFG had a higher prevalence of the MetS, cigarette smoking and use of antihypertensive and lipid-lowering therapies, increased fasting plasma glucose and triglyceride concentrations, a raised trig:HDL ratio and lower values of the McAuley index. The IFG group also had lower plasma adiponectin concentration than the normoglycaemic group, although this difference was statistically significant only in female subjects. During the study, the IFG group had a 25% increase in the prevalence of the MetS as defined by the IDF criteria, whereas the prevalence of NCEP-ATPIII-defined MetS remained unchanged. This increase in IDF-defined MetS was attributable almost solely to the increase in fasting glucose concentration that resulted in the threshold of two additional abnormal criteria, over and above central obesity, being exceeded in the majority of the IDF group. These changes were associated with an increased prevalence of IR ( þ 21%), significant increases in insulin concentration and HOMA-IR and QUICKI indices and a nonsignificant trend of deterioration in anthropometric indices. The trig:HDL ratio and plasma adiponectin remained largely unchanged throughout the study in this group.
In contrast, the normoglycaemic group showed no timerelated changes in any of the IR indices, prevalence of IR or anthropometry, with only a moderate increase in the prevalence of IDF-defined MetS ( þ 6%) being observed during the study. Despite this apparent metabolic stability, small but highly significant (Po0.001) increases in median fasting plasma glucose ( þ 0.02 mmol l
À1
) and HbA 1C ( þ 0.3%) were observed in this group.
The findings of the ROC curve analyses, expressed as areas under the curve, are shown in Table 2 . These data confirmed the above findings by showing the significant predictors of IFG, in ranking order as the IDF MetS classification, trig:HDL ratio, McAuley index, plasma adiponectin concentration and NCEP-ATPIII MetS classification. Fasting insulin concentration and the insulin/glucose-derived indices, HOMA-IR and QUICKI, did not predict the development of IFG.
Discussion
Many studies have assessed the ability of indices of IR to predict the development of type 2 diabetes. A majority of these studies have been population-based, cross-sectional surveys in patients with either impaired glucose tolerance or IFG and have used the development of diabetes as their end Predictors of glucose dysregulation in obesity BI Shand et al point. In general, these studies have shown that obesity, fasting plasma glucose and a variety of indices derived from fasting glucose, insulin and triglyceride concentrations are sensitive predictors of type 2 diabetes, and that composite models of these indices do not generally improve discriminatory power. [22] [23] [24] Our study differed from these earlier investigations by being a prospective analysis in overweight and obese subjects that compared the ability of several commonly used indices of IR with MetS classifications to predict the change from normoglycaemia to IFG, an important step in the development of diabetes. The predictive potential of the various indices was evaluated by ROC curve analysis and also by comparing the baseline values of subjects who were consistently normoglycaemic throughout the study with subjects who developed IFG. The main findings of this study were that IR markers, derived, in part, from fasting plasma triglyceride, were Predictors of glucose dysregulation in obesity BI Shand et al sensitive predictors for the development of IFG, over the medium term, in normoglycaemic, overweight and obese subjects, and that this predictive ability was similar to a diagnosis of the MetS. In contrast, indices derived from fasting glucose and insulin levels, such as the HOMA-IR and QUICKI indices, did not identify this 'at risk' group of subjects. This difference in predictive ability was probably attributable to the fact that all the study group subjects were normoglycaemic at baseline, which would have resulted in the predictive power of indices derived from glucose and insulin being attenuated, relative to the power of indices derived from triglyceride and insulin. Our data showed that the trig:HDL ratio was the strongest biochemical index for predicting the development of IFG. We also confirmed the strong relationship that exists between low circulating adiponectin levels and progression to incipient diabetes. 14 The ability of the various biochemical IR markers to predict IFG was approximately similar to that seen for the presence of the MetS. In our study group, the IDF definition had marginally greater predictive power than the NCEP-ATPIII classification. This result is in accordance with earlier studies that have reported that the two definitions have approximately equal ability to predict the development of incident type 2 diabetes, and that modifications or additions to the criteria have minimal influence on predictive power. 25, 26 Another feature of our study was that the McAuley index, trig:HDL ratio and plasma adiponectin concentration seemed to have reached close to peak abnormal values at baseline in the IFG group and then remained largely unaltered over the study period. In comparison, fasting insulin concentrations and the values of insulin/glucosederived IR indices, although not predicting the onset of IFG, increased significantly during the study. These results are consistent with the known aetiological sequence of glucose dysregulation, whereby dyslipidaemia and altered adipocytokine production contribute to the initial changes in insulin signalling pathways that lead to IR and ultimately compensatory hyperinsulinaemia. 1, 27 The importance of early identification of this change in insulin function is highlighted by the small, but highly significant, increase in mean fasting glucose concentration and HbA 1C levels that we observed in the normoglycaemic group, indicating a trend of slow and gradual deterioration in glucose control. Our finding that the characteristic lipid abnormality of the MetS, a raised trig:HDL ratio, identified subjects at the risk of developing IFG is consistent with several other reported studies. 13, 28, 29 This easily obtained ratio has been validated by comparison with euglycaemic-hyperinsulinaemic clamp data, 13 and our observation that it was the most sensitive biochemical predictor of IFG supports its use in clinical and research practice. Comparison of our results and the results of earlier investigations 13, 28, 29 showed that only 35% of our IFG group had a trig:HDL ratio 41.8 at baseline, a value that has been reported to provide maximum power for identifying at-risk individuals. 13 This suggests that lower values of the trig:HDL ratio may be of pathological importance and further studies are therefore warranted to determine the value that equates to increased risk for the development of IR. The ratio has the advantage of also assessing low-density lipoprotein-cholesterol particle size 30 and predicting cardiovascular disease, with this predictive potential being equal to the other commonly used ratios of low-density lipoprotein cholesterol to HDL cholesterol and total cholesterol to HDL cholesterol. However, to ensure valid results are obtained with the ratio, it is essential that the blood samples are collected under strict fasting conditions, as plasma triglyceride levels are subject to wide and rapid fluctuations after consumption of food. The trig:HDL ratio may also be affected by lipid-lowering agents, leading possibly to underestimation of predictive power. In our study all the samples were collected after an overnight fast and only a small proportion of the study participants had changes in their lipid therapy during the study. This study adds to the increasing volume of evidence that adiponectin is a sensitive marker of IR and a key component of the MetS. 14, 25 Adiponectin has several advantages as a marker of IR, as we have shown previously that this relationship is independent of body weight and adiposity, 16 whereas this study shows that low circulating levels of adiponectin precede the development of IFG. In comparison, changes in IR indices, derived from insulin and glucose concentrations, seem to occur later in the progression of the disease and are known to be more influenced by confounding factors, such as anthropometry and variability in fasting conditions and sample collection. This study had a number of limitations. First, the study was of medium-term duration in a relatively small number of subjects. Second, we chose to study only overweight and obese subjects, rather than including a normal-weight group, and instead used the subjects who remained classified as normoglycaemic throughout the study as the control group. However, over the relatively short duration of the study, approximately three-quarters of the study group had a deterioration in glucose control, with one-quarter developing IFG and the majority of the remaining subjects having a gradual increase in fasting glucose concentration. The magnitude of these changes gave sufficient statistical power to our study, and mitigated, to some extent, the relatively small study population and absence of a control group. Third, we measured total adiponectin concentrations rather than the more biologically active high molecular weight form of the compound, 31 as assays of the polymeric form only became available at the end of the study. In summary, this prospective study showed that indices derived, in part, from fasting plasma triglyceride concentration, identified normoglycaemic, overweight and obese individuals who progressed to IFG over a 3-year period. Indices of IR derived from fasting plasma glucose and insulin concentrations did not identify this 'at risk' group, probably because of the subjects being normoglycaemic at baseline. The study also showed that the presence of the MetS itself, and the associated increase in trig:HDL ratio and lower circulating adiponectin levels, all predicted the development of IFG. This predictive potential was marginally greater with the IDF classification than with the NCEP-ATPIII classification.
